X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3635) 3635
Publication (296) 296
Newsletter (238) 238
Book Review (76) 76
Newspaper Article (41) 41
Book Chapter (12) 12
Conference Proceeding (7) 7
Magazine Article (7) 7
Trade Publication Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
abatacept (3568) 3568
humans (2095) 2095
animals (1484) 1484
ctla-4 antigen (1397) 1397
immunoconjugates (1374) 1374
index medicus (1147) 1147
antigens, cd (1139) 1139
immunology (1063) 1063
mice (993) 993
female (991) 991
male (922) 922
rheumatoid arthritis (811) 811
rheumatology (657) 657
t-lymphocytes - immunology (587) 587
immunoconjugates - therapeutic use (583) 583
arthritis, rheumatoid - drug therapy (563) 563
antirheumatic agents - therapeutic use (526) 526
transplantation (523) 523
middle aged (520) 520
adult (473) 473
immunosuppressive agents - therapeutic use (436) 436
treatment outcome (425) 425
ctla-4 (423) 423
antigens, differentiation - genetics (410) 410
lymphocyte activation (404) 404
rheumatoid factor (403) 403
antigens, differentiation - immunology (396) 396
arthritis (391) 391
t cells (372) 372
expression (357) 357
surgery (356) 356
cd28 (353) 353
mice, inbred c57bl (350) 350
double-blind (342) 342
rituximab (340) 340
activation (334) 334
mice, inbred balb c (318) 318
aged (301) 301
research (301) 301
care and treatment (287) 287
methotrexate (286) 286
costimulation (284) 284
immunosuppressive agents - pharmacology (272) 272
cd28 antigens - immunology (268) 268
rats (267) 267
antigens, differentiation - metabolism (264) 264
in-vivo (262) 262
abatacept - therapeutic use (256) 256
antibodies, monoclonal - therapeutic use (250) 250
analysis (242) 242
b7-2 antigen (234) 234
rheumatoid-arthritis (228) 228
induction (227) 227
medicine, research & experimental (226) 226
antigens, differentiation - physiology (220) 220
tumor necrosis factor-alpha - antagonists & inhibitors (220) 220
cells, cultured (218) 218
drug therapy (218) 218
b7-1 antigen - immunology (212) 212
graft rejection - prevention & control (212) 212
disease (211) 211
lymphocytes (209) 209
time factors (209) 209
infliximab (206) 206
antirheumatic agents - adverse effects (205) 205
cd4-positive t-lymphocytes - immunology (203) 203
therapy (203) 203
immunoconjugates - pharmacology (202) 202
tolerance (197) 197
immunosuppression (192) 192
efficacy (190) 190
immunoconjugates - adverse effects (189) 189
safety (188) 188
tocilizumab (186) 186
adalimumab (184) 184
receptor (183) 183
etanercept (181) 181
transplantation, homologous (179) 179
antigen (174) 174
molecular sequence data (173) 173
graft rejection - immunology (172) 172
arthritis, rheumatoid - immunology (171) 171
cd28 antigens - metabolism (169) 169
dendritic cells (169) 169
pharmacology & pharmacy (169) 169
antigens, differentiation - pharmacology (167) 167
immunotherapy (167) 167
drug therapy, combination (164) 164
monoclonal-antibody (164) 164
t-cell activation (164) 164
t-cells (161) 161
b7-1 antigen - metabolism (156) 156
health aspects (154) 154
kidney transplantation (154) 154
lymphocyte activation - immunology (154) 154
rats, inbred lew (153) 153
antirheumatic agents (151) 151
inadequate response (150) 150
t-lymphocytes - drug effects (149) 149
risk factors (147) 147
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3688) 3688
Japanese (54) 54
German (48) 48
French (45) 45
Spanish (29) 29
Chinese (25) 25
Russian (9) 9
Czech (6) 6
Hungarian (6) 6
Portuguese (6) 6
Italian (5) 5
Polish (5) 5
Danish (3) 3
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Revue du rhumatisme, ISSN 1169-8330, 11/2016, Volume 83, p. A98-A99
Journal Article
Drugs, ISSN 0012-6667, 7/2017, Volume 77, Issue 11, pp. 1221 - 1233
The biological DMARD (bDMARD) abatacept (Orencia®), a recombinant fusion protein, selectively modulates a co-stimulatory signal necessary for T-cell... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | SUBCUTANEOUS ABATACEPT | RADIOGRAPHIC PROGRESSION | CO-STIMULATION MODULATOR | INADEQUATE RESPONSE | LONG-TERM SAFETY | PHASE IIIB | PHARMACOLOGY & PHARMACY | INTRAVENOUS ABATACEPT | TOXICOLOGY | METHOTREXATE-NAIVE PATIENTS | HEAD-TO-HEAD | DAMAGE PROGRESSION | Abatacept - pharmacology | Antirheumatic Agents - administration & dosage | Humans | Treatment Outcome | Clinical Trials as Topic | Methotrexate - therapeutic use | Methotrexate - adverse effects | Abatacept - adverse effects | Immunoconjugates - pharmacology | Arthritis, Rheumatoid - drug therapy | Abatacept - therapeutic use | Immunoconjugates - therapeutic use | Adult | Antirheumatic Agents - pharmacokinetics | Methotrexate - administration & dosage | Drug Therapy, Combination | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Antirheumatic Agents - therapeutic use | Care and treatment | Usage | Dosage and administration | Abatacept | Drug therapy | Rheumatoid arthritis | Intravenous administration | Pathogenesis | Clinical trials | Systematic review | Lymphocytes T | Arthritis | Proteins | Cell activation | Lymphocytes | Remission | Methotrexate | Fusion protein | Recombinant | Antigens | Signs and symptoms | Biological products | Rheumatology | T cell receptors | Patients | Immunogenicity | Tumor necrosis factor | Structural damage | TNF inhibitors | Cost analysis | Health risk assessment
Journal Article
U.S. Pharmacist, ISSN 0148-4818, 10/2011, Volume 36, Issue 10, pp. 60 - 68
Journal Article
Revue du rhumatisme, ISSN 1169-8330, 01/2013, Volume 80, Issue 1, p. 46
Evaluer l'efficacite de l'abatacept chez les patients ayant une spondylarthropathie (SpA) axiale refractaire au traitement par anti-TNF-[alpha]. 
Abatacept
Journal Article
Zeitschrift fur Rheumatologie, ISSN 0340-1855, 07/2009, Volume 68, Issue 5, p. 380
Der klinische Erfolg der Depletierung von B-Zellen durch den Anti-CD20-Antikorper Rituximab hat eine neue Ara in der Therapie rheumatischer Erkrankungen... 
Abatacept
Journal Article
BMC Musculoskeletal Disorders, ISSN 1471-2474, 05/2016, Volume 17, Issue 1, p. 231
Journal Article
Journal Article
Arthritis Research and Therapy, ISSN 1478-6354, 05/2017, Volume 19, Issue 1, pp. 97 - 11
Journal Article
Journal Article
Journal Article
Revue du rhumatisme, ISSN 1169-8330, 07/2019, Volume 86, Issue 4, p. 326
Resume L'obesite est une epidemie mondiale dont un nombre croissant d'elements probants suggere une influence sur la reponse de l'organisme aux traitements... 
Psoriasis | Abatacept | Lymphocytes
Journal Article
BMC Pharmacology and Toxicology, ISSN 2050-6511, 04/2016, Volume 17, Issue 1, pp. 17 - 17
Background: Abatacept (ABA) is a fusion receptor protein containing the CTLA-4 domain that prevents the activation of naive T cells by binding the CD80 and... 
Reactivation | Abatacept | Rheumatoid arthritis | Hepatitis B | RHEUMATOID-ARTHRITIS | RECOMMENDATIONS | PHARMACOLOGY & PHARMACY | TOXICOLOGY | Hepatitis B Antibodies - analysis | Hepatitis B, Chronic - immunology | Antirheumatic Agents - administration & dosage | Arthritis, Rheumatoid - blood | Humans | Male | Methotrexate - therapeutic use | Arthritis, Rheumatoid - complications | Abatacept - administration & dosage | Asymptomatic Infections | Drug Therapy, Combination - adverse effects | Arthritis, Rheumatoid - drug therapy | Lamivudine - therapeutic use | Antirheumatic Agents - adverse effects | Hepatitis B virus - immunology | Antirheumatic Agents - therapeutic use | Antiviral Agents - therapeutic use | Treatment Outcome | Biomarkers - blood | Hepatitis B virus - physiology | Arthritis, Rheumatoid - virology | DNA, Viral - blood | Hepatitis B, Chronic - virology | Hepatitis B virus - drug effects | Abatacept - adverse effects | Hepatitis B, Chronic - complications | Hepatitis B, Chronic - drug therapy | Virus Activation - drug effects | Abatacept - therapeutic use | Aged | Hepatitis B virus - isolation & purification | Infusions, Intravenous | Drug Monitoring | Corticosteroids | Dendritic cells | Immunoglobulin G | Liver | Lamivudine | Arthritis | Prednisone | T cells | Infection | Rheumatoid factor | Methotrexate | Drug therapy | Health aspects | Index Medicus
Journal Article
P and T, ISSN 1052-1372, 03/2006, Volume 31, Issue 3, pp. 149 - 153
Journal Article
by Brunner, Hermine I and Tzaribachev, Nikolay and Vega-Cornejo, Gabriel and Louw, Ingrid and Berman, Alberto and Calvo Penadés, Inmaculada and Antón, Jordi and Ávila-Zapata, Francisco and Cuttica, Rubén and Horneff, Gerd and Foeldvari, Ivan and Keltsev, Vladimir and Kingsbury, Daniel J and Viola, Diego Oscar and Joos, Rik and Lauwerys, Bernard and Paz Gastañaga, Maria Eliana and Rama, Maria Elena and Wouters, Carine and Bohnsack, John and Breedt, Johannes and Fischbach, Michel and Lutz, Thomas and Minden, Kirsten and Miraval, Tatiana and Ally, Mahmood M. T. M and Rubio-Pérez, Nadina and Solau Gervais, Elisabeth and van Zyl, Riana and Li, Xiaohui and Nys, Marleen and Wong, Robert and Banerjee, Subhashis and Lovell, Daniel J and Martini, Alberto and Ruperto, Nicolino and Becker, Mara L and Ilowite, Norman T and Dare, Jason A and Morris, Paula K and Beukelman, Timothy G and Wagner-Weiner, Linda and Zemel, Lawrence and Quartier, Pierre and Kone-Paut, Isabelle and Belot, Alexandre and Gerloni, Valeria and Ferrandiz, Manuel and Van Rensburg, Dina Janse and Scheibel, Iloite Maria and Goldstein-Schainberg, Claudia and Silva, Clovis and Terreri, Maria Teresa Sande e Lemos Ascensao and Gamir, Maria and Burgos Vargas, Ruben and Faugier Fuentes, Enrique and Cimaz, Rolando and Alessio, Maria and Espada, Graciela and Pediat Rheumatology Collaborative and Paediat Rheumatology Int Trials Or and Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)
Arthritis and Rheumatology, ISSN 2326-5191, 07/2018, Volume 70, Issue 7, pp. 1144 - 1154
Objective. To investigate the pharmacokinetics, effectiveness, and safety of subcutaneous (SC) abatacept treatment over 24 months in patients with... 
RHEUMATOID-ARTHRITIS | IMMUNOGENICITY | EFFICACY | COSTIMULATION MODULATOR ABATACEPT | INADEQUATE RESPONSE | LONG-TERM SAFETY | METHOTREXATE | INTRAVENOUS ABATACEPT | RHEUMATOLOGY | DISEASE-ACTIVITY SCORE | CHILDREN
Journal Article